Smoking increases risk of death for nasopharyngeal carcinoma survivors

Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

"While it is established that tobacco smoke is a risk factor for [the most common cancer arising from the upper part of the throat behind the nose and near the base of skull], its role in influencing survival of patients with established cancers is not known," said Fang-Yun Xie, M.D., professor in the Department of Radiation Oncology at the Sun Yat-sen University Cancer Center in Guangzhou, China. "We found that cigarette smoking does influence the survival of patients with nasopharyngeal carcinoma. Patients with a history of smoking, regardless of whether they ceased smoking for one or more years, have poorer survival than those who never smoked."

In the United States, about 2,900 people are expected to develop nasopharyngeal carcinoma in 2013, and about half of the people with this cancer are younger than 55 years old, according to the American Cancer Society. This cancer is more common in some parts of China.

"Our findings demonstrate the dangers of cigarette smoking in terms of the survival of patients. Hence, we strongly recommend that people, including those with nasopharyngeal carcinoma, do not smoke," said Xie.

Xie and colleagues followed 1,849 newly diagnosed nasopharyngeal carcinoma patients admitted to the Sun Yat-sen University Cancer Center between 2005 and 2007. They gathered information on smoking and drinking history, and demographics. The primary endpoint for the study was overall survival, and secondary endpoints were progression-free survival, locoregional relapse-free survival, and distant metastasis-free survival. Patients were followed for up to eight years.

During follow-up, 8 percent of the patients developed locoregional relapse, about 13 percent had their disease spread to distant organs, and 20 percent died of their disease.

The researchers found that among all nasopharyngeal carcinoma patients, those who smoked heavily were 3.3-fold more likely to die, 2.5-fold more likely to have their disease progress, and 2.7-fold more likely to have their disease spread to distant organs, compared with those who did not smoke. Both former and current smokers were impacted equally.

They also found a dose-response relationship between pack-years smoked and increase in risk of death or progression: the higher the pack-years, the lower the survival rate.

The findings were still significant in subgroup analyses and after adjusting for age, gender, drinking status, cancer subtype, tumor stage, spread of the disease, status of Epstein-Barr virus infection (which can cause this cancer), radiation techniques, and chemotherapy regimens.

"Previous studies have found that cancer patients resume smoking after treatment because of a higher perceived difficulty of quitting, and lower perceptions of their -related risk," said Xie. "Our finding that cigarette smoking lowers the chance of for nasopharyngeal carcinoma patients, with a dose-response relationship, is a key fact that the general audience should keep in mind."

add to favorites email to friend print save as pdf

Related Stories

Prognosis after cystectomy not affected by smoking

Oct 15, 2012

(HealthDay)—Despite the link between cigarette smoking and the development of bladder cancer, the prognosis of people with bladder cancer after undergoing a cystectomy is not affected by cigarette smoking, ...

Recommended for you

Gene test aids cancer profile

3 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

20 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.